{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["tiragolumab","atezolizumab","bevacizumab"]],"indication":"previously-treated advanced non-squamous NSCLC","name":"NCT04958811","nct_id":"NCT04958811","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04958811. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Tiragolumab 600mg IV will be administered together with atezolizumab 1200mg IV and bevacizumab 15mg/kg IV every 3 weeks (q3w) until progressive disease or unacceptable toxicity.","label":"Tiragolumab plus atezolizumab and bevacizumab","type":"EXPERIMENTAL"}],"collaborators":["Genentech, Inc."],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["Non-squamous Non-small-cell Lung Cancer"],"enrollment":{"count":29,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Tiragolumab","otherNames":[],"type":"DRUG"},{"name":"Atezolizumab","otherNames":[],"type":"DRUG"},{"name":"Bevacizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-10","lead_sponsor":"Georgetown University","official_title":"A Phase II Open-label Multi-cohort Study Evaluating the Efficacy of Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR)","timeFrame":"Up to end of treatment (average 9 months)"}],"references":[],"start_date":{"date":"2021-12-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC","url":"https://clinicaltrials.gov/study/NCT04958811"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04958811"}